Metabolic Brain Disease

, Volume 24, Issue 3, pp 415–425 | Cite as

Tyrosine administration decreases glutathione and stimulates lipid and protein oxidation in rat cerebral cortex

  • Ângela M. Sgaravatti
  • Alessandra S. Magnusson
  • Amanda S. de Oliveira
  • Andréa P. Rosa
  • Caroline Paula Mescka
  • Fernanda R. Zanin
  • Carolina D. Pederzolli
  • Angela T. S. Wyse
  • Clóvis M. D. Wannmacher
  • Moacir Wajner
  • Carlos Severo Dutra-Filho
Original Paper
First Online:
Received:
Accepted:

Abstract

Tyrosine levels are abnormally elevated in tissues and physiological fluids of patients with inborn errors of tyrosine catabolism especially in tyrosinemia type II which is caused by deficiency of tyrosine aminotransferase (TAT) and provokes eyes, skin and central nervous system disturbances. We have recently reported that tyrosine promoted oxidative stress in vitro but the exact mechanisms of brain damage in these disorder are poorly known. In the present study, we investigated the in vivo effect of L-tyrosine (500 mg/Kg) on oxidative stress indices in cerebral cortex homogenates of 14-day-old Wistar rats. A single injection of L-tyrosine decreased glutathione (GSH) and thiol-disulfide redox state (SH/SS ratio) while thiobarbituric acid-reactive substances, protein carbonyl content and glucose-6-phosphate dehydrogenase activity were enhanced. In contrast, the treatment did not affect ascorbic acid content, and the activities of superoxide dismutase, catalase and glutathione peroxidase. These results indicate that acute administration of L-tyrosine may impair antioxidant defenses and stimulate oxidative damage to lipids and proteins in cerebral cortex of young rats in vivo. This suggests that oxidative stress may represent a pathophysiological mechanism in hypetyrosinemic patients.

Keywords

Tyrosine Hypertyrosinemias Tyrosinemia type II Tyrosine administration Rat brain Oxidative stress 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This work was supported by the research grants from Programa de Núcleos de Excelência (PRONEX), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) and FINEP Rede Instituto Brasileiro de Neurociência (IBN-Net #01.06.0842-00).

References

  1. Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126CrossRefPubMedGoogle Scholar
  2. Anderson ME (1998) Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 111–112:1–14CrossRefPubMedGoogle Scholar
  3. Bongiovanni R, Yamamoto BK, Simpson C, Jaskiw GE (2003) Pharmacokinetics of systemically administered tyrosine: a comparison of serum, brain tissue and in vivo microdialysate levels in the rat. J Neurochem 87:310–317CrossRefPubMedGoogle Scholar
  4. Browne RW, Armstrong D (1998) Reduced glutathione and glutathione disulfide. Methods Mol Biol 108:347–352PubMedGoogle Scholar
  5. Ellaway CJ, Holme E, Standing S (2001) Outcome of tyrosinemia type III. J Inherit Metab Dis 24:824–832CrossRefPubMedGoogle Scholar
  6. Esterbauer H, Cheeseman KH (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 186:407–421CrossRefPubMedGoogle Scholar
  7. Goldsmith LA, Kang E, Bienfang DC, Jimbow K, Gerald P, Baden HP (1973) Tyrosinemia with plantar and palmar keratosis and keratitis. J Pediatr 83:798–805CrossRefPubMedGoogle Scholar
  8. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685–716CrossRefPubMedGoogle Scholar
  9. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J. Neurochem 97:1634–1658CrossRefGoogle Scholar
  10. Halliwell B, Gutteridge JMC (1985) Oxygen radicals and the nervous system. Trends Neurosci 8:22–26CrossRefGoogle Scholar
  11. Held PK (2006) Disorders of tyrosine catabolism. Mol Genet Metab 88:103–106CrossRefPubMedGoogle Scholar
  12. Kletzien RF, Harris PK, Foellmi LA (1994) Glucose-6-phosphate dehydrogenase: a “housekeeping” enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. FASEB J 8:174–181PubMedGoogle Scholar
  13. Lemonnier F, Charpentier C, Odievre M, Larregue M, Lemonnier A (1979) Tyrosine aminotransferase isoenzyme deficiency. J Pediatr 94:931–932CrossRefPubMedGoogle Scholar
  14. Leong SF, Clark JB (1984) Regional enzyme development in rat brain. Enzymes associated with glucose utilization. Biochem J. 218:131–138Google Scholar
  15. Light IJ, Sutherland JM, Berry HK (1973) Clinical significance of tyrosinemia of prematurity. Am J Dis Child 125:243–247PubMedGoogle Scholar
  16. Llesuy SF, Milei J, Molina H, Boveris A, Milei S (1985) Comparison of lipid peroxidation and myocardial damage induced by adriamycin and 4′-epiadriamycin in mice. Tumori 71:241–249PubMedGoogle Scholar
  17. Lock EA, Gaskin P, Ellis MK, Provan WM, Robinson M, Smith LL, Prisbylla MP, Mutter LC (1996) Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol Appl Pharmacol 141:439–447CrossRefPubMedGoogle Scholar
  18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  19. Macsai MS, Schwartz TL, Hinkle D, Hummel MB, Mulhern MG, Rootman D (2001) Tyrosinemia type II: nine cases of ocular signs and symptoms. Am J Ophthalmol 132:522–527CrossRefPubMedGoogle Scholar
  20. Mamunes P, Prince PE, Thornton NH, Hunt PA, Hitchcock ES (1976) Intellectual deficits after transient tyrosinemia in the term neonate. Pediatrics 57:675–680PubMedGoogle Scholar
  21. Marklund SL (1985) Pyrogallol autoxidation. In: Greenwald RA (ed) Handbook of methods for oxygen radical research. CRC Press, Boca Raton, pp 243–247Google Scholar
  22. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, Sarles J, de Baulny HO, Touati G (2008) NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 31:81–87CrossRefPubMedGoogle Scholar
  23. Mitchell GA, Grompe M, Lambert M, Tanguay RM (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1977–1982Google Scholar
  24. Moriarty-Craige SE, Jones DP (2004) Extracellular thiols and thiol/disulfide redox in metabolism. Annu Rev Nutr 24:481–509CrossRefPubMedGoogle Scholar
  25. Morre MC, Hefti F, Wurtman RJ (1980) Regional tyrosine levels in rat brain after tyrosine administration. J Neural Transm 49:45–50CrossRefPubMedGoogle Scholar
  26. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358CrossRefPubMedGoogle Scholar
  27. Omaye ST, Turnbull JD, Sauberlich HE (1979) Selected methods for the determination of ascorbic acid in animal cells, tissues, and fluids. Methods Enzymol 62:3–11CrossRefPubMedGoogle Scholar
  28. Rabinowitz LG, Williams LR, Anderson CE, Mazur A, Kaplan P (1995) Painful keratoderma and photophobia: hallmarks of tyrosinemia type II. J Pediatr 126:266–269CrossRefPubMedGoogle Scholar
  29. Reznick AZ, Parker L (1993) Free radicals and antioxidants in muscular neurological diseases and disorders. In: Poli G, Albano E, Dianzani MU (eds) Free radicals: from basic science to medicine. Birkäuser Verlag, Basel, pp 425–437Google Scholar
  30. Reznick AZ, Packer L (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 233:357–363CrossRefPubMedGoogle Scholar
  31. Rice ME, Russo-Menna I (1998) Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. Neuroscience 82:1213–1223CrossRefPubMedGoogle Scholar
  32. Rice DN, Houston IB, Lyon IC, Macarthur BA, Mullins PR, Veale AM, Guthrie R (1989) Transient neonatal tyrosinaemia. J Inherit Metab Dis 12:13–22CrossRefPubMedGoogle Scholar
  33. Russo PA, Mitchell GA, Tanguay RM (2001) Tyrosinemia: a review. Pediatr Dev Pathol 4:212–221CrossRefPubMedGoogle Scholar
  34. Sgaravatti AM, Vargas BA, Zandoná BR, Deckmann KB, Rockenbach FJ, Moraes TB, Monserrat JM, Sgarbi MB, Pederzolli CD, Wyse ATS, Wannmacher CMD, Wajner M, Dutra-Filho CS (2008) Tyrosine promotes oxidative stress in cerebral cortex of young rats. Int J Dev Neurosci 26:551–559CrossRefPubMedGoogle Scholar
  35. Shasi Vardhan K, Pratap Rudra MP, Rao SL (1997) Inhibition of tyrosine aminotransferase by beta-N-oxalyl-L-alpha, beta-diaminopropionic acid, the Lathyrus sativus neurotoxin. J Neurochem 68:2477–2484PubMedCrossRefGoogle Scholar
  36. Stadtman ER, Levine RL (2003) Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 25:207–218CrossRefPubMedGoogle Scholar
  37. Valikhani M, Akhyani M, Jafari AK, Barzegari M, Toosi S (2005) Oculocutaneous tyrosinaemia or tyrosinaemia type 2: a case report. J Eur Acad Dermatol Venereol 20:591–594CrossRefGoogle Scholar
  38. Wajner M, Latini A, Wyse AT, Dutra-Filho CS (2004) The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J Inherit Metab Dis 27:427–448CrossRefPubMedGoogle Scholar
  39. Wendel A (1981) Glutathione peroxidase. Methods Enzymol 77:325–333CrossRefPubMedGoogle Scholar
  40. Zahler WL, Cleland WW (1968) A specific and sensitive assay for disulfides. J Biol Chem 243:716–719PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Ângela M. Sgaravatti
    • 2
  • Alessandra S. Magnusson
    • 1
  • Amanda S. de Oliveira
    • 1
  • Andréa P. Rosa
    • 1
  • Caroline Paula Mescka
    • 1
  • Fernanda R. Zanin
    • 1
  • Carolina D. Pederzolli
    • 2
  • Angela T. S. Wyse
    • 1
    • 2
  • Clóvis M. D. Wannmacher
    • 1
    • 2
  • Moacir Wajner
    • 1
    • 2
  • Carlos Severo Dutra-Filho
    • 1
    • 2
  1. 1.Departamento de Bioquímica, Instituto de Ciências Básicas da SaúdeUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  2. 2.Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da SaúdeUniversidade Federal do Rio Grande do SulPorto AlegreBrazil

Personalised recommendations